European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma June 8, 2022June 27, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA approves Roche’s Lunsumio, a first-in-class…CHMP recommends EU conditional approval of Roche’s…FDA grants Priority Review to Roche’s Lunsumio for…FDA grants priority review to Roche’s bispecific…New pivotal data demonstrate clinical benefit of…New pivotal data demonstrate clinical benefit of…
